Cost effectiveness of memantine in Alzheimer's disease in the UK

References

• Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–2117
   PubMed Web of Science ®Google Scholar
• Matthews F, Brayne C. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS Med 2005; 2: e193
   PubMed Web of Science ®Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387–403
   PubMed Web of Science ®Google Scholar
• Jönsson L, Wimo A. The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics 2009; 27: 391–403
   PubMed Web of Science ®Google Scholar
• Luengo- Fernandez R, Leal J, Gray A. Dementia 2010 – The economic burden of dementia and associated research funding in the United Kingdom. Health Economics Research Centre, University of Oxford for the Alzheimer's Research Trust, 2010, www.dementia2010.org
   Google Scholar
• Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21: 607–620
   PubMed Web of Science ®Google Scholar
• Livingston G, Katona C, Roch B, et al. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care – the LASER-AD study. Curr Med Res Opin 2004; S7: 1007–1016
   Google Scholar
• Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333–1341
   PubMed Web of Science ®Google Scholar
• Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277: 806–812
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, Migliaccio-Walle K, et al. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 2001; 57: 964–971
   PubMed Web of Science ®Google Scholar
• Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2005; 23: 1271–1282
   PubMed Web of Science ®Google Scholar
• Rive B, Le Reun C, Grishchenko M, et al. Predicting time to full-time care in AD: a new model. J Med Econ 2010; 13: 362–370
   PubMedGoogle Scholar
• Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20–27
   PubMed Web of Science ®Google Scholar
• Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14: 704–715
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5: 83–89
   PubMed Web of Science ®Google Scholar
• Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2007; 11: 471–449
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 136–143
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317–324
   PubMed Web of Science ®Google Scholar
• Hasselblad V, McCrory DC. Meta-analytic tools for medical decision making: a practical guide. Med Decis Making 1995; 15: 81–96
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560
   PubMed Web of Science ®Google Scholar
• NICE - Guide to the methods of technology appraisal. www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
   Google Scholar
• Radosevitch DM, Pruitt M. Twelve-item health status questionnaire (HSQ–12) cooperative validation project: comparability study. Poster presented at the AHSR FHSR Annual Meeting, 1996.
   Google Scholar
• Ferm L. Behavioural activities in demented geriatric patients. Study based on evaluations made by nursing staff members and on patients’ scores on a simple psychometric test. Gerontol Clin (Basel) 1974; 16: 185–194
   PubMedGoogle Scholar
• Logsdon RG, Gibbons LE, McCurry SM, et al. Quality of life in Alzheimer's disease: patient and caregiver reports. J Ment Health Ageing 1999; 5: 21–32
   Google Scholar
• Sapin C, Livingston G, Katona C, et al. Main factors influencing preference-based utility values in Alzheimer's disease: results from the LASER–AD Study. Poster presented at the 7th International Conference on Alzheimer's and Parkinson's Disease (AD/PD), Sorrento, Italy, March 9-13, 2005.
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095–1108
   PubMed Web of Science ®Google Scholar
• Beecham J, Knapp MRJ. Costing psychiatric intervention. Measuring Mental Health Needs, GJ Thornicroft, CR Brewin, JK Wing. Gaskell, London 1992
   Google Scholar
• Curtis L. Unit Costs of Health and Social Care 2009, Personal Social Services Research Unit. University of Kent, Canterbury 2009
   Google Scholar
• Lundbeck Data on File.
   Google Scholar
• Foreign exchange rates: European Union http://www.hmrc.gov.uk/exrate/european-union.htm
   Google Scholar
• Department of Health – National Dementia Strategy http://www.dh.gov.uk/en/socialcare/deliveringadultsocialcare/olderpeople/nationaldementiastrategy/index.htm
   Google Scholar
• Caro J, Getsios D, Migliaccio-Walle K, et al. AHEAD Study Group. Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis. BMC Geriatr 2003; 3: 6
   Google Scholar
• Ward A, Caro JJ, Getsios D, et al. AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry. 2003; 18: 740–747
   Google Scholar
• Caro JJ, Salas M, Ward A, et al. Assessment of Health Economics in Alzheimer's Disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002; 14: 84–89
   PubMed Web of Science ®Google Scholar